KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Net Income (2017 - 2025)

Historic Net Income for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to -$30.7 million.

  • Biomarin Pharmaceutical's Net Income fell 12898.19% to -$30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 6147.43%. This contributed to the annual value of $426.9 million for FY2024, which is 15462.08% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Net Income of -$30.7 million as of Q3 2025, which was down 12898.19% from $240.5 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Net Income high stood at $240.5 million for Q2 2025, and its period low was -$57.9 million during Q4 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's median Net Income value was $40.4 million (recorded in 2023), while the average stood at $56.2 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Net Income crashed by 44001.64% in 2021, and later surged by 828273.09% in 2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Net Income (Quarter) stood at -$57.9 million in 2021, then surged by 99.57% to -$249000.0 in 2022, then skyrocketed by 8282.73% to $20.4 million in 2023, then surged by 513.22% to $124.9 million in 2024, then plummeted by 124.61% to -$30.7 million in 2025.
  • Its Net Income was -$30.7 million in Q3 2025, compared to $240.5 million in Q2 2025 and $185.7 million in Q1 2025.